Application of WHONET in the Analysis of Pseudomonas aeruginosa Resistance to Imipenem and Meropenem

Othman Ahmad, Rawezh; Ahmadi, Amjad; Bahmani, Nasrin; Taherpour, Arezou

doi:10.30699/ijmm.17.5.606

year 17, Issue 5 (September - October 2023) Iran J Med Microbiol 2023, 17(5): 606-612 | Back to browse issues page

‎ 10.30699/ijmm.17.5.606

Mendeley

Zotero

RefWorks

Othman Ahmad R, Ahmadi A, Bahmani N, Taherpour A. Application of WHONET in the Analysis of Pseudomonas aeruginosa Resistance to Imipenem and Meropenem. Iran J Med Microbiol 2023; 17 (5) :606-612
URL: http://ijmm.ir/article-1-2100-en.html

Application of WHONET in the Analysis of Pseudomonas aeruginosa Resistance to Imipenem and Meropenem

Rawezh Othman Ahmad¹

, Amjad Ahmadi²

, Nasrin Bahmani³

, Arezou Taherpour

⁴

1- Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran
2- Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
3- Zoonoses Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
4- Department of Microbiology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran , rezaeeit93@gmail.com

Abstract: (677 Views)

Background and Aim: WHONET software is a database for analyzing microbiology data, specifically antibiotic resistance patterns. Pseudomonas aeruginosa is a significant agent of nosocomial infections and has been identified as a critical priority by the World Health Organization (WHO). The aim of this study was to monitor the resistance patterns of imipenem and meropenem over one year (February 2022-February 2023) using WHONET software 2022.
Materials and Methods: A total of 95 P. aeruginosa isolates were obtained from Kowsar Hospital in Sanandaj, Iran. After verification through biochemical tests and 16sRNA PCR, an antibiogram test was performed for each isolate based on The Clinical & Laboratory Standards Institute (CLSI) guidelines. Data were analyzed using WHONET 2022.
Results & Conclusion: Pseudomonas aeruginosa isolates were obtained from 44 females and 51 males. Of all isolates, the WHONET analysis showed that resistance to imipenem and meropenem was 87.4% and 64.2%, respectively. The WHONET database can be an appropriate software for analyzing and monitoring bacterial susceptibility and resistance, especially for critical priority bugs such as P. aeruginosa.

Keywords: Imipenem, Meropenem, Pseudomonas aeruginosa, WHONET

Full-Text [PDF 767 kb] (79 Downloads) | | Full-Text (HTML) (136 Views)

Type of Study: Brief Original Article | Subject: Antibiotic Resistance
Received: 2023/06/19 | Accepted: 2023/09/21 | ePublished: 2023/11/29

References

1. Yalda M, Sadat TZ, Elham RMN, Mohammad TS, Neda M, Mohammad M. Distribution of Class 1-3 Integrons in Carbapenem-Resistant Pseudomonas aeruginosa Isolated from Inpatients in Shiraz, South of Iran. Ethiop J Health Sci. 2021;31(4):719-24.

2. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia. 2012;16(4):303-7.

3. Abdeta A, Negeri AA, Beyene D, Adamu E, Fekede E, Fentaw S, et al. Prevalence and Trends of Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter Species Isolated from Clinical Specimens at the Ethiopian Public Health Institute, Addis Ababa, Ethiopia: A Retrospective Analysis. Infect Drug Resist. 2023;16:1381-90. [DOI:10.2147/IDR.S403360] [PMID] [PMCID]

4. Pottier M, Gravey F, Castagnet S, Auzou M, Langlois B, Guérin F, et al. A 10-year microbiological study of Pseudomonas aeruginosa strains revealed the circulation of populations resistant to both carbapenems and quaternary ammonium compounds. Sci Rep. 2023;13(1):2639. [DOI:10.1038/s41598-023-29590-0] [PMID] [PMCID]

5. Elshamy AA, Aboshanab KM. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Future Sci OA. 2020;6(3):FSO438. [DOI:10.2144/fsoa-2019-0098] [PMID] [PMCID]

6. Lister Philip D, Wolter Daniel J, Hanson Nancy D. Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms. Clin Microbiol Rev. 2009;22(4):582-610. [DOI:10.1128/CMR.00040-09] [PMID] [PMCID]

7. World Health O. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. World Health Organization; 2017.

8. Vaez H, Salehi-Abargouei A, Ghalehnoo ZR, Khademi F. Multidrug Resistant Pseudomonas aeruginosa in Iran: A Systematic Review and Metaanalysis. J Glob Infect Dis. 2018;10(4):212-7. [DOI:10.4103/jgid.jgid_113_17] [PMID] [PMCID]

9. Heidari R, Farajzadeh Sheikh A, Hashemzadeh M, Farshadzadeh Z, Salmanzadeh S, Saki M. Antibiotic resistance, biofilm production ability and genetic diversity of carbapenem-resistant Pseudomonas aeruginosa strains isolated from nosocomial infections in southwestern Iran. Mol Biol Re. 2022;49(5):3811-22. [DOI:10.1007/s11033-022-07225-3] [PMID] [PMCID]

10. Weinstein M, Lewis J, Bobebchick A, (). Performance Standards for Antimicrobial Susceptibility Testing, CLSI supplement M100. 2021.

11. Hassuna NA, Darwish MK, Sayed M, Ibrahem RA. Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa. Infect Drug Resist. 2020;13:285-93. [DOI:10.2147/IDR.S233808] [PMID] [PMCID]

12. Lyu J, Chen H, Bao J, Liu S, Chen Y, Cui X, et al. Clinical Distribution and Drug Resistance of Pseudomonas aeruginosa in Guangzhou, China from 2017 to 2021. J Clin Med. 2023;12(3):1189. [DOI:10.3390/jcm12031189] [PMID] [PMCID]

13. Sonal S, Anuj S, Amala AA, Pandey A, Kochhar A, Mittal A, et al. Delhi's network for surveillance of antimicrobial resistance: The journey, challenges and output from first year. Indian J Med Microbiol. 2023;41:19-24. [DOI:10.1016/j.ijmmb.2022.12.001] [PMID]